In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on AnaptysBio, with a price target of $51.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the potential positive outcomes from AnaptysBio’s legal dispute with Tesaro, a subsidiary of GSK, regarding the 2014 Collaboration Agreement for Jemperli. AnaptysBio has filed a lawsuit alleging that Tesaro breached exclusivity provisions and failed to maximize Jemperli’s commercial potential. If AnaptysBio prevails, it could regain all rights to Jemperli, allowing it to find a new commercial partner and potentially increase its financial returns.
Despite the uncertainties surrounding the litigation, Bodnar sees limited risk for Tesaro to win, given the clear terms of the agreement and AnaptysBio’s right to make a claim. The company’s strategic plans, including a planned Biopharma Co and Royalty Co split in 2026, remain unchanged, indicating confidence in their legal position. This combination of factors contributes to Bodnar’s Buy rating for AnaptysBio’s stock.
In another report released on November 12, J.P. Morgan also maintained a Buy rating on the stock with a $67.00 price target.